Zydus and SIFI from Italy announce marketing alliance to launch Innovative Intraocular Lenses

Zydus and SIFI from Italy announce marketing alliance to launch Innovative Intraocular Lenses

Zydus Cadila, the global pharmaceutical major and SIFI, the Italian leader in the development of therapeutic solutions to treat ophthalmic disorders have tied up to market innovative IOLs (Intraocular lenses) and surgical products developed in Italy and licensed in India by SIFI.

SIFI’s innovative IOLs (Intraocular lenses) have been approved by the Indian Central Drugs Standards Control Organization (Directorate General of Health Services) and Ministry of Health & Family Welfare (Medical Device and Diagnostic Division). These surgical devices represent the most advanced solution for cataract refractive surgery and the correction of astigmatism (a condition where the cornea is irregularly shaped) and presbyopia (natural loss of near focusing ability that occurs with age).

‘Refractive cataract’ is nowadays at the frontier of cataract surgery as it combines clouded lens removal to the simultaneous correction of refractive errors such as myopia, hypermetropia, astigmatism and presbyopia, in order to free the patient from wearing glasses following the surgery. The highly advanced IOLs for this purpose are the EDOF (Extended Depth of Focus) lenses that present an optical plate with a continuous series of focuses, able to ensure a continuum correction from far to near in case of presbyopia and in case of astigmatism to provide compensation of the corneal abnormal curvature. Zydus and SIFI look forward to bringing such innovations to India and to the entire South Asia region in order to empower surgeons with an advanced technology and consequently better the quality of vision and life of patients.

Zydus receives final approval from the USFDA for Bosentan Tablets & Trientine Hydrochloride Capsules

Zydus Cadila has received the final approval from the USFDA to market Bosentan Tablets USP (US RLD – Tracleer Tablets), 62.5 mg and 125 mg and Trientine Hydrochloride Capsules USP (US RLD – Syprine Capsules), 250 mg. Both the products will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Bosentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1). This medication blocks the effects of endothelin-1, which helps lower blood pressure in the lungs, slow the worsening of symptoms from the disease and improves ability to exercise. Trientine is a chelating agent. It works by removing a heavy metal (copper) from the blood. It is used to treat the Wilson’s disease, a genetic metabolic defect that causes excess copper to build up in the body. Trientine is used to treat this inherited condition in people who cannot take penicillamine. The group now has 265 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.